Drug Trial News

RSS

New drug zilebesiran effectively lowers blood pressure for six months, study finds

A single injection of the experimental medication zilebesiran was safe and effective in reducing systolic blood pressure in people with mild-to-moderate high blood pressure for up to six months, as detailed in the Phase 2 of the KARDIA study, reported as late-breaking science today at the American Heart Association's Scientific Sessions 2023.

13 Nov 2023

Single injection of new medication effectively eliminates Lp(a) for nearly one year

In the first human trial of a new therapeutic, a single injection of lepodisiran reduced levels of lipoprotein(a), or Lp(a), to undetectable levels for nearly one year, according to late-breaking science presented today at the American Heart Association's Scientific Sessions 2023.

13 Nov 2023

SELECT trial: Semaglutide reduces cardiovascular events by 20% in overweight or obese patients without diabetes

Findings from a multi-center, international clinical trial reported by a Cleveland Clinic physician show that semaglutide reduced cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease who do not have diabetes.

13 Nov 2023

AdvanCell reaches milestone as first prostate cancer patient dosed with 212Pb-ADVC001

AdvanCell, a radiopharmaceutical company developing a pipeline of Targeted Alpha Therapies for cancer patients, today announced the first patient was treated with 212Pb-ADVC001, a Targeted Alpha Therapy in development for the treatment of PSMA-positive metastatic Castration-Resistant Prostate Cancer (mCRPC).

13 Nov 2023

Clinical trial underway for novel human milk-based microbiome therapy

In a breakthrough for human milk science, researchers at City of Hope, Los Angeles, have dosed the first patient in a Phase 2a clinical trial evaluating a novel therapy for blood cancer patients undergoing allogeneic hematopoietic stem cell transplantation.

10 Nov 2023

Obinutuzumab shows promise in preserving kidney function, preventing flares in lupus nephritis patients

In a post hoc analysis of the phase 2 NOBILITY trial, researchers found that treatment with obinutuzumab-;an antibody that targets a protein expressed on certain immune cells-;was superior to placebo for preserving kidney function and preventing flares in patients with lupus nephritis, a kidney condition associated with the autoimmune disease lupus.

10 Nov 2023

Mucosal vaccine shows lasting defense against SARS-CoV-2 Omicron in primate study

In this groundbreaking study, researchers developed a mucosal adenoviral-vector vaccine, ChAd-SARS-CoV-2-S, which demonstrated sustained and robust immunity against a challenging Omicron variant in nonhuman primates, indicating a promising direction for durable COVID-19 protection strategies. Unlike traditional intramuscular vaccines, this mucosal vaccine elicited a comprehensive immune response, potentially paving the way for more effective and long-lasting COVID-19 vaccines.

9 Nov 2023

FORTE accrues first 1000 participants for highly anticipated colorectal cancer prevention trial

FORTE (NRG-CC005) is a highly anticipated colorectal cancer prevention trial led by NRG Oncology examining surveillance colonoscopy intervals in participants who have non-advanced polyps.

9 Nov 2023

Patients with advanced HER2-positive breast cancer live longer if treated with pyrotinib, trial shows

Patients with HER2-positive breast cancer that has started to spread to other parts of the body survive for longer if they are treated with a new drug called pyrotinib, according to results from the longest follow-up of the PHOEBE randomized clinical trial in China.

8 Nov 2023

Study compares the immunogenicity and safety of two SARS-CoV-2 vaccines

The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019. Since then, extensive efforts have been made to develop and evaluate vaccines to combat the virus.

8 Nov 2023

UTHSC's drug candidate for advanced prostate cancer goes to first clinical trial

A drug candidate developed by researchers at the University of Tennessee Health Science Center for advanced metastatic castration-resistant prostate cancer is now in its first clinical trial.

6 Nov 2023

Targeted drug may offer a new treatment option for patients with relapsed blood cancer

A new targeted drug, studied by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), may offer a new treatment option for patients with blood cancers, including chronic lymphocytic leukemia (CLL) and Non-Hodgkin lymphoma (NHL) whose disease has stopped responding to standard treatments.

6 Nov 2023

Sotagliflozin provides kidney and heart benefits in patients with diabetes and chronic kidney disease

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, which are medications that lower blood sugar levels among other effects, provide kidney- and heart-related benefits to patients with and without diabetes.

3 Nov 2023

High-impact clinical trial results to be presented at ASN Kidney Week 2023

The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2023 November 1–November 5.

3 Nov 2023

Docetaxel improves survival in men with high-grade prostate cancer and low PSA

Men with high-grade prostate cancer and low prostate-specific antigen (PSA) levels have a poor prognosis.

1 Nov 2023

Clinical trial demonstrates the effectiveness of ALS drug in treating people with acute spinal cord injuries

A small clinical trial with a pharmacokinetic sub-study, led by a world-renowned pharmacologist at the University of Houston, has demonstrated the promising effectiveness of the drug Riluzole for improving functionality in people with acute spinal cord injuries (SCI) if the drug is taken within 12 hours post-injury.

1 Nov 2023

The development of a machine-learned scoring function of human preference in the context of early drug discovery campaigns

In a recent study published in Nature Communications, researchers developed a scoring mechanism based on artificial intelligence for early drug discovery campaigns that might be utilized for compound prioritizing, motif rationalization, and biased drug design.

1 Nov 2023

University of Cincinnati to lead NIH StrokeNet for next five years

The University of Cincinnati and UC Health have been renewed as the National Coordinating Center of the National Institutes of Health (NIH) StrokeNet, which is the primary infrastructure for multicenter trials of stroke funded by NIH and the pipeline for new potential treatments for adults and children with stroke and those at risk for stroke.

30 Oct 2023

New treatment combination shows promise for metastatic colorectal cancer patients with rare genetic mutation

An international Phase 3 clinical trial found that metastatic colorectal cancer patients with a rare genetic tumor mutation called KRAS G12C experienced superior progression-free survival rates compared to standard of care when offered a combination treatment of KRAS inhibitor sotorasib and monoclonal antibody panitumumab.

27 Oct 2023

Breast cancer screening trial expands internationally to enhance diversity

A clinical trial led by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) demonstrates how diversity among study participants is vital for reducing outcomes disparities.

27 Oct 2023

Previous
1
...
11
12
13
14
15
16
17
...
1143
Next

Drug Trial News

New drug zilebesiran effectively lowers blood pressure for six months, study finds

Single injection of new medication effectively eliminates Lp(a) for nearly one year

SELECT trial: Semaglutide reduces cardiovascular events by 20% in overweight or obese patients without diabetes

AdvanCell reaches milestone as first prostate cancer patient dosed with 212Pb-ADVC001

Clinical trial underway for novel human milk-based microbiome therapy

Obinutuzumab shows promise in preserving kidney function, preventing flares in lupus nephritis patients

Mucosal vaccine shows lasting defense against SARS-CoV-2 Omicron in primate study

FORTE accrues first 1000 participants for highly anticipated colorectal cancer prevention trial

Patients with advanced HER2-positive breast cancer live longer if treated with pyrotinib, trial shows

Study compares the immunogenicity and safety of two SARS-CoV-2 vaccines

UTHSC's drug candidate for advanced prostate cancer goes to first clinical trial

Targeted drug may offer a new treatment option for patients with relapsed blood cancer

Sotagliflozin provides kidney and heart benefits in patients with diabetes and chronic kidney disease

High-impact clinical trial results to be presented at ASN Kidney Week 2023

Docetaxel improves survival in men with high-grade prostate cancer and low PSA

Clinical trial demonstrates the effectiveness of ALS drug in treating people with acute spinal cord injuries

The development of a machine-learned scoring function of human preference in the context of early drug discovery campaigns

University of Cincinnati to lead NIH StrokeNet for next five years

New treatment combination shows promise for metastatic colorectal cancer patients with rare genetic mutation

Breast cancer screening trial expands internationally to enhance diversity

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News